Trials in High Point, North Carolina
Here are the top 10 medical studies for colorectal cancer in High Point, North Carolina
Popular Filters
Phase 3 Trials
PD-L1 Inhibitor
XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer
Recruiting2 awardsPhase 3
Charlotte, North Carolina
This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Chemotherapy
ctDNA Testing for Colon Cancer Treatment Prediction
Recruiting1 awardPhase 2 & 3
Pittsburgh, Pennsylvania
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Chemotherapy
Nivolumab + Ipilimumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Roanoke, Virginia
This trial is testing nivolumab with or without ipilimumab as a treatment for metastatic colorectal cancer in patients with microsatellite instability high or mismatch repair deficiency. The goal is to see if the combination therapy is more effective than nivolumab alone and if either treatment is more effective than chemotherapy.
Chemotherapy
Pump Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Durham, North Carolina
"This trial is comparing using a special pump to deliver chemotherapy directly to the liver along with regular chemotherapy versus regular chemotherapy alone for patients with colorectal cancer that has spread to the liver and cannot be removed by
Chemotherapy
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Durham, North Carolina
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Chemotherapy
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Durham, North Carolina
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
Trials With No Placebo
Kinase Inhibitor
BGB-3245 + Panitumumab for Colorectal Cancer
Recruiting1 awardPhase 1
Durham, North Carolina
"This trial aims to assess the safety and effectiveness of a combination of BGB-3245 and panitumumab in patients with advanced colorectal cancer. The study will determine the maximum tolerated dose
PD-L1 Inhibitor
XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer
Recruiting2 awardsPhase 3
Charlotte, North Carolina
This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Monoclonal Antibodies
ABBV-400 for Advanced Solid Cancers
Recruiting1 awardPhase 1
Durham, North Carolina
This trial tests a new drug called ABBV-400 for adults with advanced cancers. The study aims to find the best dose and see how well it works, both alone and with other treatments. Patients will receive the drug through an IV and be closely monitored for effects and side effects.
Chemotherapy
ctDNA Testing for Colon Cancer Treatment Prediction
Recruiting1 awardPhase 2 & 3
Pittsburgh, Pennsylvania
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.